コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 l mechanism for the early crescendo phase of neonatal seizures.
2 nic acid and flurothyl models of symptomatic neonatal seizures.
3 l and diazepam, two drugs in current use for neonatal seizures.
4 Q channels may be effective for treatment of neonatal seizures.
5 metanide might be an effective treatment for neonatal seizures.
6 etanide should be useful in the treatment of neonatal seizures.
7 ng the diagnosis, aetiology and treatment of neonatal seizures.
8 irth weight is a significant risk factor for neonatal seizures.
9 f these infants were diagnosed with clinical neonatal seizures.
10 charge after resolution of acute symptomatic neonatal seizures.
11 an add-on to phenobarbital for treatment of neonatal seizures.
12 tion could be a viable approach for treating neonatal seizures.
13 arge for most infants with acute symptomatic neonatal seizures.
14 0 minutes, meconium aspiration syndrome, and neonatal seizures, adjusted for maternal height, materna
17 is study estimated the incidence of clinical neonatal seizures among infants born between 1992 and 19
18 h, an Apgar score of 3 or less at 5 minutes, neonatal seizure, an umbilical-artery blood pH of 7.05 o
20 In one family, the phenotype extends beyond neonatal seizures and includes rolandic seizures, and a
21 le deleterious effects of GABAergic drugs on neonatal seizures and on excitotoxic neuronal injury in
22 a clinically relevant target for refractory neonatal seizures and provide insights for future drug d
23 ng mutations responsible for benign familial neonatal seizures and/or peripheral nerve hyperexcitabil
24 re often hypotensive, needed intubation, had neonatal seizures, and received a clinical diagnosis of
29 This is of particular concern for treating neonatal seizures, as early life exposure to drugs such
32 nt compounds inhibit motor manifestations of neonatal seizures but not cortical seizure activity.
33 ear in understanding the basis for a form of neonatal seizures can be attributed to the successful po
37 GABAergic) drugs, the standard treatment for neonatal seizures, can have excitatory effects in the ne
39 ificates, death certificates, and a study of neonatal seizures conducted concurrently with this study
41 nked lethal disorder involving cleft palate, neonatal seizures, contractures, central nervous system
42 nfant with ISOD who initially presented with neonatal seizures, diffusion restriction noted on magnet
45 Compared with controls, rats subjected to neonatal seizures had impaired learning and decreased ac
46 e absence of controlled trials, treatment of neonatal seizures has changed minimally despite poor dru
48 odent model of the most common form of human neonatal seizures, hypoxia-induced seizures (HS), we aim
49 approaches to the diagnosis and treatment of neonatal seizures, identifies some of the critical facto
51 d bumetanide added to phenobarbital to treat neonatal seizures in the first trial to include a standa
53 s 0-3 at 5 minutes, meconium aspiration, and neonatal seizures increased similarly with maternal BMI.
54 echanism for phenobarbital inefficacy during neonatal seizures is the reduced abundance and function
56 lifetime is found in the neonatal period and neonatal seizures lead to a propensity for epilepsy and
59 y pH <7.0), hypoxic ischemic encephalopathy, neonatal seizures, neonatal respiratory support for grea
62 se to antidepressant exposure; the impact of neonatal seizures on dentate gyrus neurogenesis; and the
66 ted channelopathies, such as benign familial neonatal seizures or peripheral nerve hyperexcitability
67 of an unknown prior diagnosis of epilepsy or neonatal seizures) or classified as not having epilepsy
68 pothesis that neonatal encephalopathy, early neonatal seizures, or both result from early antenatal i
70 nd in children affected with benign familial neonatal seizures (R213W mutation) or with neonatal epil
72 with the primary outcome measure) from 9 US Neonatal Seizure Registry centers, born from July 2015 t
73 [corrected] and need for resuscitation, and neonatal seizures-signs commonly attributed to birth asp
74 sted the hypothesis that a single episode of neonatal seizures (sNS) on rat postnatal day (P) 7 perma
75 ing that KCC2 phosphorylation regulates both neonatal seizure susceptibility and CLP290-mediated KCC2
76 recent insights about the pathophysiology of neonatal seizures that may provide the foundation for be
78 eptic disorders ranging from benign familial neonatal seizures to severe epileptic encephalopathies.
79 In a CD-1 mouse model of refractory ischemic neonatal seizures, treatment with the KCC2 functional en
80 piration) scores less than 7 or less than 4; neonatal seizure; ventilator support; neonatal intensive
85 ve mutation in KCNQ2 that has a phenotype of neonatal seizures without permanent clinical CNS impairm